ESR1 and breast carcinoma: This hypothesis has been confirmed by our results showing that various chromatin markers were dramatically altered in the ERα promoter by EGCG treatment accompanied by corresponding alterations in the activities of histone modification-related enzymes such as HDACs and HATs in ERα-negative breast cancer cells.